Translational research on esophageal adenocarcinoma: From cell line to clinic

Diseases of the Esophagus

Volumn 28, Issue 1, 2015, Pages 90-96

  Boonstra, J J ^a,b   Tilanus, H W ^b   Dinjens, W N M ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Barrett's esophagus; Cell line; Esophageal adenocarcinoma; Esophagus; in vitro model

Indexed keywords

ADENOCARCINOMA CELL LINE; CANCER CELL LINE; CARCINOGENESIS; CELL CULTURE; CELL DIVISION; CELL STRUCTURE; CONTAMINATION; CULTURE TECHNIQUE; DISPERSION; ESOPHAGEAL ADENOCARCINOMA; FIBROBLAST; GENETIC SIMILARITY; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH; ADENOCARCINOMA; ANIMAL; ESOPHAGUS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84921593553     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/dote.12095     Document Type: Review

References (49)

1. Jemal A, Bray F, Center M M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Attwood S E, Harrison L A, Preston S L, Jankowski J A. Esophageal adenocarcinoma in 'mice and men': back to basics! Am J Gastroenterol 2008; 103: 2367-2372.
3. Garman K S, Orlando R C, Chen X. Review: experimental models for Barrett's esophagus and esophageal adenocarcinoma. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1231-1243.
4. Wang X, Ouyang H, Yamamoto Y etal. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell 2011; 145: 1023-1035.
5. Li Y, Martin R C 2nd. Reflux injury of esophageal mucosa: experimental studies in animal models of esophagitis, Barrett's esophagus and esophageal adenocarcinoma. Dis Esophagus 2007; 20: 372-378.
6. Chen X X, Yang G Y, Ding W Y, Bondoc F, Crutis S K, Yang C S. An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis 1999; 20: 1801-1807.
7. Rizvi S, Demars C J, Comba A etal. Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis. Cancer Res 2010; 70: 6787-6796.
8. Boonstra J J, van Marion R, Beer D G etal. Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst 2010; 102: 271-274.
9. Kuriya Y, Kitamura M, Akaishi T etal. A new cell line (TE-3) derived from human squamous cell carcinoma of the esophagus. Tohoku J Exp Med 1983; 139: 377-387.
10. Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 1993; 119: 441-449.
11. Altorki N, Schwartz G K, Blundell M, Davis B M, Kelsen D P, Albino A P. Characterization of cell lines established from human gastric-esophageal adenocarcinomas. Biologic phenotype and invasion potential. Cancer 1993; 72: 649-657.
12. Trauth B C, Klas C, Peters A M etal. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305.
13. Rockett J C, Larkin K, Darnton S J, Morris A G, Matthews H R. Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer 1997; 75: 258-263.
14. de Both N J, Wijnhoven B P, Sleddens H F, Tilanus H W, Dinjens W N. Establishment of cell lines from adenocarcinomas of the esophagus and gastric cardia growing in vivo and in vitro. Virchows Arch 2001; 438: 451-456.
15. Kan T, Shimada Y, Sato F etal. Gene expression profiling in human esophageal cancers using cDNA microarray. Biochem Biophys Res Commun 2001; 286: 792-801.
16. Alvarez H, Koorstra J B, Hong S M etal. Establishment and characterization of a bona fide Barrett esophagus-associated adenocarcinoma cell line. Cancer Biol Ther 2008; 7: 1753-1755.
17. Wijnhoven B P, Tilanus M G, Morris A G, Darnton S J, Tilanus H W, Dinjens W N. Human oesophageal adenocarcinoma cell lines JROECL 47 and JROECL 50 are admixtures of the human colon carcinoma cell line HCT 116. Br J Cancer 2000; 82: 1510-1512.
18. Boonstra J J, van der Velden A W, Beerens E C etal. Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7. Cancer Res 2007; 67: 7996-8001.
19. Leedham S J, Preston S L, McDonald S A etal. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 2008; 57: 1041-1048.
20. Rosenberg C, Geelen E, IJszenga M J etal. Spectrum of genetic changes in gastro-esophageal cancer cell lines determined by an integrated molecular cytogenetic approach. Cancer Genet Cytogenet 2002; 135: 35-41.
21. Nancarrow D J, Handoko H Y, Smithers B M etal. Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2008; 68: 4163-4172.
22. Kosoff R E, Gardiner K L, Merlo L M, Pavlov K, Rustgi A K, Maley C C. Development and characterization of an organotypic model of Barrett's esophagus. J Cell Physiol 2012; 227: 2654-2659.
23. Underwood T J, Derouet M F, White M J etal. A comparison of primary oesophageal squamous epithelial cells with HET-1A in organotypic culture. Biol Cell 2010; 102: 635-644.
24. Honing J, Meijer C, Plukker J T M, Kruyt F A E. Abstract 5360: towards identification of cancer stem cells in esophageal adenocarcinoma. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR. Cancer Res 2012; 72 (8 Suppl): Abstract nr 5360. doi:1538-7445.AM2012-5360.
25. Zhao R, Quaroni L, Casson A G. Identification and characterization of stemlike cells in human esophageal adenocarcinoma and normal epithelial cell lines. J Thorac Cardiovasc Surg 2012; 144: 1192-1199.
26. Gros S J, Kurschat N, Dohrmann T etal. Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma. Mol Cancer Ther 2010; 9: 2037-2045.
27. Bruyere C, Lonez C, Duray A etal. Considering temozolomide as a novel potential treatment for esophageal cancer. Cancer 2011; 117: 2004-2016.
28. Sharma S V, Haber D A, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 2010; 10: 241-253.
29. McDermott U, Sharma S V, Dowell L etal. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007; 104: 19936-19941.
30. Paterson A L, Shannon N B, Lao-Sirieix P etal. A systematic approach to therapeutic target selection in oesophago-gastric cancer. Gut 2012. doi: 10.1136/gutjnl-2012-302039
31. Dahlberg P S, Jacobson B A, Dahal G etal. ERBB2 amplifications in esophageal adenocarcinoma. Ann Thorac Surg 2004; 78: 1790-1800.
32. Porte H, Triboulet J P, Kotelevets L etal. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin Cancer Res 1998; 4: 1375-1382.
33. Herrera L J, El-Hefnawy T, Queiroz de Oliveira P E etal. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia 2005; 7: 75-84.
34. Houldsworth J, Cordon-Cardo C, Ladanyi M, Kelsen D P, Chaganti R S. Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res 1990; 50: 6417-6422.
35. Jankowski J, Coghill G, Hopwood D, Wormsley K G. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 1992; 33: 1033-1038.
36. Watson G A, Zhang X, Stang M T etal. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia 2006; 8: 949-955.
37. Safran H, Dipetrillo T, Akerman P etal. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 67: 405-409.
38. Bang Y J, Van Cutsem E, Feyereislova A etal. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
39. Donahue J M, Nichols F C, Li Z etal. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 2009; 87: 392-398; discussion 8-9.
40. O'Donovan T R, O'Sullivan G C, McKenna S L. Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy 2011; 7: 509-524.
41. Lynam-Lennon N, Reynolds J V, Pidgeon G P, Lysaght J, Marignol L, Maher S G. Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma. Radiat Res 2010; 174: 703-711.
42. Hong J, Katsha A, Lu P, Shyr Y, Belkhiri A, El-Rifai W. Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma. Cancer Res 2012; 72: 4504-4514.
43. Hummel R, Watson D I, Smith C etal. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 2011; 15: 429-438.
44. Paulson T G, Maley C C, Li X etal. Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 2009; 15: 3305-3314.
45. Beroukhim R, Mermel C H, Porter D etal. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
46. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude G F. Abnormal centrosome amplification in the absence of p53. Science 1996; 271: 1744-1747.
47. Wistuba I I, Bryant D, Behrens C etal. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res 1999; 5: 991-1000.
48. Jones S, Chen W D, Parmigiani G etal. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008; 105: 4283-4288.
49. Gazdar A F, Gao B, Minna J D. Lung cancer cell lines: useless artifacts or invaluable tools for medical science? Lung Cancer 2010; 68: 309-318.